One of the most investigated immune-activating ligands is CD40L because it constitutes an interesting target in cancer immunotherapy because of its ability to stimulate Th1 immunity via maturation of dendritic cells and to drive M2 to M1 macrophage differentiation [50]. This evidence concerns the gene CD40LG and cancer.